Apalutamide
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-APALUTAMIDE |
|---|---|
| Type | Drug |
| Aliases | ErleadaАпалутамід |
| Status | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-PROSTATE-2024 SRC-NCCN-PROSTATE-2025 |
Drug Facts
| Class | Androgen receptor pathway inhibitor (ARPI) |
|---|---|
| Mechanism | AR antagonist similar to enzalutamide; FDA-approved for nmCRPC (SPARTAN) and mHSPC (TITAN). |
| Typical dosing | 240 mg PO once daily. |
| Ukraine registered | True |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Notes
Distinguishing AE from enzalutamide: rash is class-marker and notable. Fewer cognitive AEs than enzalutamide (less CNS penetration).
Used By
Regimens
REG-ADT-APALUTAMIDE- ADT + apalutamide (continuous)